Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought_老虎社区_美港股上老虎

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought

Motley Fool2021-10-12

Key Points Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower. ARK Invest ETFs also added shares of a healthcare middleman ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

S土豪熊貓G
·2021-10-12
Let’s go Cathie!
回复
4
举报
收起
- 滚股怪:
  Go
  2021-10-12
  回复
  举报
Alagu
·2021-10-12
Damn she loves to sell good stocks and load up on trash.
回复
1
举报
收起
- miaomee:
  Agreed
  2021-10-12
  回复
  举报
JB0112
·2021-10-12
Mama mia
回复
2
举报
ppyys
·2021-10-12
Comment and like
回复
2
举报
收起
- miaomee:
  Comment n like bakc pls
  2021-10-12
  回复
  举报
JeremyChuax
·2021-10-12
Like and comment.
回复
3
举报
收起
- JeremyChuax:
  Ip
  2021-10-12
  回复
  举报
- miaomee:
  Like and comment pls
  2021-10-12
  回复
  举报
RobinChanKH
·2021-10-12
Gogo
回复
2
举报
SirBahamut
·2021-10-12
Yay
回复
4
举报
Newbie_21
·2021-10-12
Good...
回复
6
举报
收起
- 滚股怪:
  Yes good
  2021-10-12
  回复
  举报
SCP03
·2021-10-12
Nice
回复
4
举报
收起
- SaveHK:
  go go Cathie🎉🎊🥳🚀🚀🚀🚀🚀
  2021-10-12
  回复
  举报
Sriwonc
·2021-10-12
Like pls
回复
6
举报
收起
- Jen88:
  Ok
  2021-10-12
  回复
  举报
- KHYAP:
  🤞🏼
  2021-10-12
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1105330036?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-12 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105330036","market":"us","top_or_hot":-1,"title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","media":"Motley Fool","content":"<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGFY","symbol_name":"Signify Health, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","article_id":"1105330036","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","pubTimestamp":1634032364,"sourceInfo":null,"weMediaInfo":null,"summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGFY":"Signify Health, Inc.","ARKK":"ARK Innovation ETF","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"translate_title":"凯西·伍德去垃圾箱跳水：她刚买了3只下垂的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKK":0.9,"BEAM":0.9,"DNA":0.9,"SGFY":0.9},"content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":826553845,"gmtCreate":1634041356112,"gmtModify":1634041376103,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Let’s go Cathie!","listText":"Let’s go Cathie!","text":"Let’s go Cathie!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826553845","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6174268,"gmtCreate":1634042831060,"gmtModify":1634637700164,"authorId":4091089381144950,"author":{"id":4091089381144950,"idStr":"4091089381144950","authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826553845,"type":1,"supId":0,"prevId":0,"content":"Go","text":"Go","html":"Go"}],"langContent":"CN"},{"id":826583116,"gmtCreate":1634037707116,"gmtModify":1634038444564,"author":{"id":"3570022529586181","authorId":"3570022529586181","name":"Alagu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3570022529586181","authorIdStr":"3570022529586181"},"htmlText":"Damn she loves to sell good stocks and load up on trash.","listText":"Damn she loves to sell good stocks and load up on trash.","text":"Damn she loves to sell good stocks and load up on trash.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826583116","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6173733,"gmtCreate":1634039347974,"gmtModify":1634637746444,"authorId":3569375896365334,"author":{"id":3569375896365334,"idStr":"3569375896365334","authorId":3569375896365334,"name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826583116,"type":1,"supId":0,"prevId":0,"content":"Agreed","text":"Agreed","html":"Agreed"}],"langContent":"CN"},{"id":826512098,"gmtCreate":1634037083365,"gmtModify":1634037199801,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"htmlText":"Mama mia","listText":"Mama mia","text":"Mama mia","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826512098","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":826519967,"gmtCreate":1634036642325,"gmtModify":1634036642573,"author":{"id":"3581756384979769","authorId":"3581756384979769","name":"ppyys","avatar":"https://static.tigerbbs.com/610302822a164d13f68b36645cef259a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581756384979769","authorIdStr":"3581756384979769"},"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826519967","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6173734,"gmtCreate":1634039358419,"gmtModify":1634637746336,"authorId":3569375896365334,"author":{"id":3569375896365334,"idStr":"3569375896365334","authorId":3569375896365334,"name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826519967,"type":1,"supId":0,"prevId":0,"content":"Comment n like bakc pls","text":"Comment n like bakc pls","html":"Comment n like bakc pls"}],"langContent":"CN"},{"id":826534774,"gmtCreate":1634036313341,"gmtModify":1634036313669,"author":{"id":"4089499026613770","authorId":"4089499026613770","name":"JeremyChuax","avatar":"https://static.tigerbbs.com/a1f1ede120de2da723e4456d7fdcce55","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4089499026613770","authorIdStr":"4089499026613770"},"htmlText":"Like and comment.","listText":"Like and comment.","text":"Like and comment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/826534774","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6173441,"gmtCreate":1634036318534,"gmtModify":1634637768715,"authorId":4089499026613770,"author":{"id":4089499026613770,"idStr":"4089499026613770","authorId":4089499026613770,"name":"JeremyChuax","avatar":"https://static.tigerbbs.com/a1f1ede120de2da723e4456d7fdcce55","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826534774,"type":1,"supId":0,"prevId":0,"content":"Ip","text":"Ip","html":"Ip"},{"id":6173736,"gmtCreate":1634039366181,"gmtModify":1634637746118,"authorId":3569375896365334,"author":{"id":3569375896365334,"idStr":"3569375896365334","authorId":3569375896365334,"name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826534774,"type":1,"supId":6173441,"prevId":0,"content":"Like and comment pls","text":"Like and comment pls","html":"Like and comment pls"}],"langContent":"CN"},{"id":826536784,"gmtCreate":1634035817232,"gmtModify":1634035817534,"author":{"id":"3585125163446793","authorId":"3585125163446793","name":"RobinChanKH","avatar":"https://static.tigerbbs.com/bf0ba843eca17a8812677bc4f2a46162","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3585125163446793","authorIdStr":"3585125163446793"},"htmlText":"Gogo","listText":"Gogo","text":"Gogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826536784","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":826536393,"gmtCreate":1634035737795,"gmtModify":1634035738067,"author":{"id":"3581734227956830","authorId":"3581734227956830","name":"SirBahamut","avatar":"https://static.tigerbbs.com/98035de918c1759870078e69640b8281","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581734227956830","authorIdStr":"3581734227956830"},"htmlText":"Yay","listText":"Yay","text":"Yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826536393","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":826595635,"gmtCreate":1634034617160,"gmtModify":1634034671517,"author":{"id":"3581562486795328","authorId":"3581562486795328","name":"Newbie_21","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581562486795328","authorIdStr":"3581562486795328"},"htmlText":"Good...&nbsp;","listText":"Good...&nbsp;","text":"Good...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826595635","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6174164,"gmtCreate":1634042287728,"gmtModify":1634637709786,"authorId":4091089381144950,"author":{"id":4091089381144950,"idStr":"4091089381144950","authorId":4091089381144950,"name":"滚股怪","avatar":"https://static.tigerbbs.com/b67621b4133ca0db91bff9766152a448","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826595635,"type":1,"supId":0,"prevId":0,"content":"Yes good","text":"Yes good","html":"Yes good"}],"langContent":"CN"},{"id":826596940,"gmtCreate":1634034356516,"gmtModify":1634034356911,"author":{"id":"3561986763872297","authorId":"3561986763872297","name":"SCP03","avatar":"https://static.tigerbbs.com/2abf42c22b2629cf57b473d657ee801e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3561986763872297","authorIdStr":"3561986763872297"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826596940","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6173285,"gmtCreate":1634034472770,"gmtModify":1634637780075,"authorId":3570678493691973,"author":{"id":3570678493691973,"idStr":"3570678493691973","authorId":3570678493691973,"name":"SaveHK","avatar":"https://static.tigerbbs.com/89b74f5799a23844400ed6de94296d38","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826596940,"type":1,"supId":0,"prevId":0,"content":"go go Cathie🎉🎊🥳🚀🚀🚀🚀🚀","text":"go go Cathie🎉🎊🥳🚀🚀🚀🚀🚀","html":"go go Cathie🎉🎊🥳🚀🚀🚀🚀🚀"}],"langContent":"CN"},{"id":826501473,"gmtCreate":1634032518783,"gmtModify":1634032519027,"author":{"id":"3586424409701165","authorId":"3586424409701165","name":"Sriwonc","avatar":"https://static.tigerbbs.com/264a5cfcdc2db585d9b139a4c4d7b11d","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3586424409701165","authorIdStr":"3586424409701165"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/826501473","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points\n<ul>\n <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li>\n <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li>\n <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li>\n</ul>\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).\n<img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\n<img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\n<img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-12 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nKey Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman ...\n\n<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","SGFY":"Signify Health, Inc.","DNA":"Ginkgo Bioworks Holdings Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6173163,"gmtCreate":1634032830852,"gmtModify":1634637788911,"authorId":3582993517958198,"author":{"id":3582993517958198,"idStr":"3582993517958198","authorId":3582993517958198,"name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826501473,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6173270,"gmtCreate":1634034260515,"gmtModify":1634637781272,"authorId":3562150941808297,"author":{"id":3562150941808297,"idStr":"3562150941808297","authorId":3562150941808297,"name":"KHYAP","avatar":"https://static.tigerbbs.com/134bef1736613cccadcb5091adcc32aa","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":826501473,"type":1,"supId":0,"prevId":0,"content":"🤞🏼","text":"🤞🏼","html":"🤞🏼"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":63,"commentSize":10,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}